EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States.

Its product pipeline in development includes Aumolertinib, an EGFR inhibitor for the treatment of ?EGFR-mutated? non-small cell lung cancer (NSCLC); Sugemalimab, an anti-PD-L1 antibody for the treatment of ?stage III and IV ?NSCLC; Lerociclib, a CDK4/6 inhibitor to treat HR+/HER2- breast cancer; and EQ176, an anti-PD-1?antibody for the treatment of liver cancer.

The company has partnerships with Exscientia and AbCellera Biologics Inc.

EQRx, Inc. was founded in 2020 and is based in Cambridge, Massachusetts.